Rapidx

Company Overview

Snapshot

Founded in January 2008 by Idan Tamir, Rapidx operated with 1–10 employees. The company secured $1M in total capital across two funding rounds from two investors.

Business overview

Rapidx developed self-administered rapid blood diagnostic tests designed for discreet home use across various health conditions. The company's core technology integrated the lancet, blood collection, and rapid diagnostic test into a single, affordable, and disposable device, aiming to address the pain and contamination risks associated with traditional blood extraction. Rapidx served the growing point-of-care (POC) and homecare markets, operating within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Diagnostics Devices.

Strategic signal

Rapidx ceased operations in January 2023, indicating a significant strategic shift and the conclusion of its business activities. This event signals to investors and innovation teams that the company is no longer active in the market, marking the end of its development and commercialization efforts in rapid diagnostic testing.

Company Intelligence Q&A

When was Rapidx founded?

Rapidx was founded in January 2008.

What was the outcome of Rapidx's clinical trial?

Rapidx completed a clinical trial at Tel Aviv Medical Center with 30 volunteers, which demonstrated faster blood extraction and less pain compared to the gold-standard technique performed by nurses.

What is the current status of Rapidx?

Rapidx is currently non-active, having ceased operations in January 2023.

Did Rapidx secure any grants?

Rapidx secured a grant from the Office of the Chief Scientist.